MedTrace Logo

Multiomics Targeting Microbiome Associated Changes in Stroke Patients (StrokeMicroBiomics)

NCT04315922 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-10-15

No results posted yet for this study

Summary

Preclinical research has established a convincing connection between changes in the gut microbiota composition and stroke outcome. However clinical data on the gut-brain axis, and its chronic characteristics, is sparse. Additional investigations in the context of ischemic stroke regarding the relationship between dysbiosis and functional changes of the microbiome, as characterized by the metabolome, are still required. The StrokeMicroBiomics study will offer insight into these mechanisms and offer new potential targets for therapeutic interventions.

The primary objective is the characterisation of gut dysbiosis in ischemic stroke patients in the acute phase after stroke and during a 3 month follow-up period.

The secondary objectives include the identification of dysregulated gut microbiome metabolites and key immune cell populations in addition to the clinical progression of the study participants during the 3 month follow-up period after disease onset.

Conditions

Interventions

DIAGNOSTIC_TEST

Microbiome and Plasma Characterisation

Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing

Sponsors & Collaborators

  • University of Luxembourg

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-16
Primary Completion
2022-12-01
Completion
2023-06-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04315922 on ClinicalTrials.gov